Holen Sie sich die Stockscreener-App
0.17
37.06%
-0.1001
Handel nachbörslich:
.16
-0.01
-5.88%
Quince Therapeutics Inc Aktie (QNCX) Neueste Nachrichten
Quince’s eDSP on ice after Neat phase III fails in A-T - BioWorld MedTech
Quince Therapeutics’ Fruit Spoils As Phase III A-T Study Falls To Ground - Citeline News & Insights
This Codere Online Luxembourg Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday - Benzinga
Quince Therapeutics (QNCX) Downgraded by Citizens to Market Perf - GuruFocus
Quince Therapeutics stock rating downgraded to Hold by D. Boral Capital By Investing.com - Investing.com Nigeria
Quince Therapeutics stock rating downgraded to Hold by D. Boral Capital - Investing.com Canada
QNCX Downgraded to 'Hold' by D. Boral Capital Analyst | QNCX Sto - GuruFocus
Lucid Capital Markets downgrades Quince Therapeutics stock to Sell after failed trial - Investing.com
Quince Therapeutics Stock Collapses After Key Trial Update In Rare Genetic Disease - Benzinga
Quince Therapeutics (NASDAQ:QNCX) Cut to Market Perform at Citizens Jmp - MarketBeat
Quince Therapeutics (QNCX) Downgraded Following Phase 3 Trial Mi - GuruFocus
Quince Therapeutics’ (QNCX) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World
Quince Therapeutics stock rating downgraded by Citizens after Phase 3 trial failure - Investing.com
Quince Therapeutics phase 3 trial for rare disease fails to meet endpoints By Investing.com - Investing.com South Africa
Why Did QNCX Stock Plummet Over 90% Today? - Asianet Newsable
Quince Therapeutics Announces Results from Phase 3 NEAT Trial - TradingView
QNCX Stock Plummets 88% After Ceasing eDSP Development - GuruFocus
QNCX Strategizes to Conserve Resources and Evaluate Opportunitie - GuruFocus
Quince Therapeutics phase 3 trial for rare disease fails to meet endpoints - Investing.com Canada
Quince Therapeutics Halts Development of Neurological Drug Candidate; Shares Plunge - marketscreener.com
Quince Therapeutics drops after co's drug fails to meet main goal in late-stage trial - TradingView
Quince Therapeutics (QNCX) Faces Setback with Phase 3 Trial Resu - GuruFocus
Quince Therapeutics stock tumbles after failed Phase 3 trial results - Investing.com
Quince Therapeutics Announces Topline Results from Pivotal Phase 3 NEAT Clinical Trial of eDSP in Ataxia-Telangiectasia - Business Wire
Is Quince Therapeutics Inc. stock showing strong momentumFed Meeting & Free Fast Entry Momentum Trade Alerts - mfd.ru
Quince Therapeutics (NASDAQ:QNCX) Given "Buy" Rating at D. Boral Capital - MarketBeat
QNCX: D. Boral Capital Maintains Buy Rating and Price Target | Q - GuruFocus
Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting - BioSpace
Quince's Clinical Trial Fails to Meet Key Endpoints - Intellectia AI
Quince Therapeutics (QNCX) Highlights Safety of Long-Term Treatm - GuruFocus
Ideas Watch: Is Quince Therapeutics Inc stock showing strong momentumProduct Launch & AI Based Buy and Sell Signals - baoquankhu1.vn
Citizens reiterates Market Outperform rating on Quince Therapeutics stock - Investing.com
Is Quince Therapeutics (NASDAQ:QNCX) Using Debt Sensibly? - simplywall.st
Investor Mood: Can Synergy CHC Corp weather a recessionStop Loss & Precise Buy Zone Identification - baoquankhu1.vn
Quince Therapeutics, Inc. (NASDAQ:QNCX) Sees Significant Growth in Short Interest - MarketBeat
Weekly Recap: Can Quince Therapeutics Inc sustain its profitabilityJuly 2025 Price Swings & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Stock Traders Buy Large Volume of Quince Therapeutics Call Options (NASDAQ:QNCX) - MarketBeat
QNCX Sees Increased Price Target Amidst Maintained Buy Rating | - GuruFocus
Panic Selling: Will Quince Therapeutics Inc stock deliver strong dividend growth2025 Market WrapUp & Verified High Yield Trade Plans - Bộ Nội Vụ
Levels Update: Is Quince Therapeutics Inc stock showing strong momentumQuarterly Profit Report & Weekly High Potential Stock Alerts - baoquankhu1.vn
Volume Summary: Why Quince Therapeutics Inc stock appeals to analystsMarket Performance Report & Low Risk Entry Point Guides - Bộ Nội Vụ
Quince Therapeutics: Good Potential In Orphan Disease In Q1 With Platform Potential - Seeking Alpha
Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Can Quince Therapeutics Inc. stock beat market expectations this quarterFit and Size Notes & lightweight options for faster days - Улправда
Citizens reiterates Market Outperform rating on Quince Therapeutics stock By Investing.com - Investing.com Nigeria
Can Quince Therapeutics Inc. stock sustain institutional interestJuly 2025 Rallies & Daily Volume Surge Signals - Улправда
Returns Recap: How Quince Therapeutics Inc. stock compares to industry benchmarksTrade Risk Assessment & Risk Managed Investment Entry Signals - Улправда
Will Quince Therapeutics Inc. stock outperform value stocksPortfolio Risk Assessment & Minimal Capital Trading Tips - Улправда
Quince Therapeutics reports Q3 EPS (25c), consensus (22c) - MSN
Quince Therapeutics, Inc. (NASDAQ:QNCX) Sees Large Growth in Short Interest - MarketBeat
1.27%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):